NASDAQ
CLDX

Celldex Therapeutics Inc

IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
LIFE SCIENCES

Prices are adjusted according to historical splits.

Celldex Therapeutics Inc Stock Price

Vitals

Today's Low:
$34.5500
Today's High:
$36.5200
Open Price:
$35.3400
52W Low:
$19.85
52W High:
$46.8
Prev. Close:
$35.3500
Volume:
376722

Company Statistics

Market Cap.:
$1.617 billion
Book Value:
7.81
Revenue TTM:
$0.001 billion
Operating Margin TTM:
-11097%
Gross Profit TTM:
$-0.049 billion
Gross Profit TTM:
$-0.049 billion
Profit Margin:
0%
Return on Assets TTM:
-18.8%
Return on Equity TTM:
-36.4%

Company Profile

Celldex Therapeutics Inc had its IPO on 1990-03-26 under the ticker symbol CLDX.

The company operates in the LIFE SCIENCES sector and IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry. Celldex Therapeutics Inc has a staff strength of 0 employees.

Stock update

Shares of Celldex Therapeutics Inc opened at $35.34 at the start of the last trading session i.e. 2022-11-02.

The stocks traded within a range of $34.55 - $36.52, and closed at $34.58.

This is a -2.18% slip from the previous day's closing price.

A total volume of 376,722 shares were traded at the close of the day’s session.

In the last one week, shares of Celldex Therapeutics Inc have increased by +1.71%.

Celldex Therapeutics Inc's Key Ratios

Celldex Therapeutics Inc has a market cap of $1.617 billion, indicating a price to book ratio of 4.544 and a price to sales ratio of 1965.24.

In the last 12-months Celldex Therapeutics Inc’s revenue was $0.001 billion with a gross profit of $-0.049 billion and an EBITDA of $-0.088 billion. The EBITDA ratio measures Celldex Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Celldex Therapeutics Inc’s operating margin was -11097% while its return on assets stood at -18.8% with a return of equity of -36.4%.

In Q2, Celldex Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 95.3%.

Celldex Therapeutics Inc’s PE and PEG Ratio

Forward PE
-
Trailing PE
-
PEG
0

Its diluted EPS in the last 12-months stands at $-1.725 per share while it has a forward price to earnings multiple of - and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Celldex Therapeutics Inc’s profitability.

Celldex Therapeutics Inc stock is trading at a EV to sales ratio of 1587.13 and a EV to EBITDA ratio of -14.8. Its price to sales ratio in the trailing 12-months stood at 1965.24.

Celldex Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$0.000 billion
Total Liabilities
$0.000 billion
Operating Cash Flow
$0.000 billion
Capital Expenditure
$0.000 billion
Dividend Payout Ratio
0%

Celldex Therapeutics Inc ended 1970 with $0.000 billion in total assets and $131.2 billion in total liabilities. Its intangible assets were valued at $0.000 billion while shareholder equity stood at $0.000 billion.

Celldex Therapeutics Inc ended 1970 with $0.000 billion in deferred long-term liabilities, $0.000 billion in other current liabilities, billion in common stock, $0.000 billion in retained earnings and $0.000 billion in goodwill. Its cash balance stood at $0.000 billion and cash and short-term investments were $0.000 billion. The company’s total short-term debt was $0.000 billion while long-term debt stood at $0.000 billion.

Celldex Therapeutics Inc’s total current assets stands at $0.000 billion while long-term investments were $0.000 billion and short-term investments were $0.000 million. Its net receivables were $0.000 billion compared to accounts payable of $0.000 billion and inventory worth $0.000 billion.

In 1970, Celldex Therapeutics Inc's operating cash flow was $0.000 billion while its capital expenditure stood at $0.000 billion.

Comparatively, Celldex Therapeutics Inc paid $0 billion in dividends in 1970.

Other key metrics

Current Trading Price
$34.58
52-Week High
$46.8
52-Week Low
$19.85
Analyst Target Price
$65.17

Celldex Therapeutics Inc stock is currently trading at $34.58 per share. It touched a 52-week high of $46.8 and a 52-week low of $46.8. Analysts tracking the stock have a 12-month average target price of $65.17.

Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 0% are held by institutions.

Frequently Asked Questions About Celldex Therapeutics Inc

The stock symbol (also called stock or share ticker) of Celldex Therapeutics Inc is CLDX

The IPO of Celldex Therapeutics Inc took place on 1990-03-26

Similar Industry Stocks (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES)

Last Price
Chg
Chg%
$0.35
-0.01
-2.14%
$2.5
-0.1
-3.85%
$1.93
-0.04
-2.03%
$51.1
-2.11
-3.97%
$68.89
-3.83
-5.27%

Most Active

Last Price
Chg
Chg%
$58.63
-1.03
-1.73%
$92.12
-4.67
-4.82%
$5.12
-0.61
-10.65%
Apple Inc (AAPL)
$145.03
-5.62
-3.73%
$0.06
0.01
+12.74%

Top Gainers

Last Price
Chg
Chg%
$73
42.7
+140.92%
Oi S.A (OIBR-C)
$0
0
+100%
$0.02
0.01
+100%
$0.25
0.1
+66.44%
$2.85
1.01
+54.86%

Top Losers

Last Price
Chg
Chg%
$5.36
-22.58
-80.82%
$0.02
-0.06
-78.67%
Air T, Inc (AIRTW)
$0.01
-0.03
-75%
$4.51
-5.17
-53.41%
$11.5
-12.2
-51.48%

About

Celldex Therapeutics, Inc., a biopharmaceutical company, is dedicated to the development of therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. The company is headquartered in Hampton, New Jersey.

Address

53 FRONTAGE ROAD, SUITE 220, HAMPTON, NJ, US